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Summary Perforin (PFP) is a cytotoxic protein released from killer cells. PFP immunoreactivity in human
peripheral blood lymphocytes (PBL) and tumour infiltrating lymphocytes (TIL) was investigated
immunocytochemically with the aid of an anti-PFP monoclonal antibody. PFP was detected in the cytoplasm
of 10% of PBL. We performed a double staining of PFP + cells with Leul lb/CD16, Leu2a/CD8, or
Leu3a/CD4 and showed that PFP was produced by 9% of CD8 + cells and 18% of CD16 + cells but not by
CD4 + cells. In 28 colorectal cancer tissues, PFP immunoreactivity was observed in the lymphocytes
infiltrating to the tumour stroma. The PFP + cells were most numerous in Dukes A and decreased in number
according to the progression of tumours. The PFP + cells in TIL exhibited the same phenotypes as those in
PBL but the PFP + cells were more numerous in CD8 + cells than in CD16 + cells at all stages. This study
represents the first evidence that PFP is mainly secreted from CD8 + cells in tumour tissues. It is hypothesised
that the decrease in the number of PFP + cells in accordance with tumour progression may reflect the
suppression of the host's local immunity.
Perforin (PFP) is a cytotoxic protein contained in the cyto-
plasmic granules of killer cells (Masson & Tschopp, L985;
Podack et al., 1985; Young et al., 1986a). PFP released from
killer cells forms pores on the target cell membrane and
induces cell lysis (Henkart, 1985; Zalman et al., 1986; Young
et al., 1986b). Recent success in the cloning of PFP cDNA
(Shinkai et al., 1988a; Lichtenheld et al., 1988; Lichtenheld &
Podack, 1989; Lowrey et al., 1989) has allowed the examina-
tion of mRNA expression of PFP in killer cells. In the T cell
lines, PFP gene expression was ascertained in the cytotoxic T
lymphocytes (CTL) and natural killer (NK) cells, but not in
helper T (Th) cells (Shinkai et al., 1988a; Lichtenheld et al.,
1988).
The role of tumour infiltrating lymphocytes (TIL) in the
defense mechanism of a tumour-bearing host has been
thoroughly reported (Werkmeister et al., 1979). It is known
that CTL and NK cells directly kill tumour cells (Reinherz et
al., 1979; Lanier et al., 1983; Lanier et al., 1986). In human
cancer tissues, PFP may be derived from CTL and NK cells
and may play an important role in anti-tumour activity.
In this paper, we aimed to identify the phenotypes of
human peripheral blood lymphocytes (PBL) and TIL, which
produce PFP. We employed a double staining method using
both anti-PFP antibody and antibodies against surface
markers of lymphocytes. Furthermore, we investigated the
relation of PFP and tumour progression in human colorectal
cancer stroma.
Materials and methods
Cellpreparation
Human PBL were prepared from healthy persons. Briefly,
PBL were recovered from the intermediate layer of Lympho-
cyte Separate Medium and suspended in RPMI 1640. The
cells were cytocentrifuged (400 r.p.m.; 9 min), fixed in 4@C
acetone for 10 min, in 4% paraformaldehyde for 10 min at
room temperature, and then transferred to 0.05 mol 1' Tris
-HCI (pH 7.6).
Tumour tissue preparation
Fresh specimens of 28 human colorectal cancer tissues were
frozen in OCT compound and kept frozen at - 80°C. Four
micron-thick sections were prepared from each sample and
fixed in acetone and 4% paraformaldehyde as described
under. These samples were analysed with immunohisto-
chemical staining for PFP and with haematoxylin and eosin
staining for morphology. The clinicopathologic analyses were
carried out according to the criteria of Dukes classification.
Eight of the 28 subjects were early cancer cases, eight were
advanced without metastasis, and twelve were advanced with
metastasis. Based on these findings, eight of the cases were
classified as Dukes A, eight as Dukes B and 12 as Dukes C.
Histological examination revealed that all of the tumours
were adenocarcinomas and showed a normal differentiation
distribution (17 cases; well differentiated, ten cases;
moderately differentiated one case; poorly differentiated).
Normal colorectal tissues, 10 cm distant from the tumours,
were used as controls.
Immunostaining
Single staining A modification of the immunoglobulin
enzyme bridge technique (ABC complex method) was used.
Briefly, non specific binding was blocked by treatment with
2% (v/v) normal rabbit serum (Vector) for 30 min. Primary
monoclonal antibody to recombinant PFP (rPFP), kindly
provided by Dr Okumura (University of Juntendo Medical
School), was applied to the sections at a dilution of 1:500,
and incubated for 60 min at room temperature. After the
sections were washed three times in Tris-HCI for 30 min,
biotinylated second antibody of rabbit anti-rat IgG (mouse
IgG adsorbed) (Vector) was applied at a dilution of 1:250,
incubated for 30 min at room temperature, and washed three
times in Tris-HCI. After quenching the endogenous peroxi-
dase activity for 20 min in distilled water containing 0.1%
NaN3 and 1% (v/v) hydrogen peroxidase, freshly prepared
ABC complex (Vectastain R ABC Kit, Vector) was applied
and followed by incubation for 30 min. After the excess
complex was washed out, the localisation of PFP was
visualised by incubating the sections for 5 min in freshly
prepared Tris-HCI containing both 0.02% (w/v) 3.3'-
diaminobenzidine tetrahydrochloride (Sigma, St Louis, MO)
and 0.03% (v/v) hydrogen peroxide. The nuclei were
counterstained with haematoxylin.
Double staining After blocking non specific binding by
treatment with 2% (v/v) normal serum (Vector) for 30 min,
primary monoclonal antibodies to Leu Ib, Leu2a or Leu3a
(Vector) were applied to each section at a dilution of 1:25,
and incubated for 2 h at room temperature. After the sec-
tions were washed three times in Tris-HCI for 30 min,
biotinylated second antibody of goat anti-mouse IgM for
Leul lb (Vector) or horse anti-mouse IgG for Leu2a and
Leu3a (rat IgG adsorbed) (Vector) was applied at a dilution
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of 1:250, incubated for 30 min at room temperature and
washed three times in Tris-HCl. After quenching the
endogenous alkaline phosphatase activity in 1% (w/v)
levamisol hydrochloride (Aldrich Chemical Company. Inc.)
for 5 min, the sections were incubated in avidin-biotinylated
alkaline phosphatase complex (Vector) for 30min. After the
excess complex was washed out, the localisation of CD16 +,
CD8 + and CD4 + cells was visualised by incubating the
sections for 10 min with an A.P. Substrate Kit 3, Blue
(Maker Code SK 5000 300, Vector). The sections were then
immunostained for PFP as described above. The sections
were also counterstained with methylgreen.
Controls
For negative controls, we prepared the antibody preabsorbed
by rPFP: Wells of an immobilon ELISA titer plate
(Dynatech-Logo) were incubated overnight with approxi-
mately 500 ng of rPFP in 50 microliters of PBS to bind rPFP
to the plastic. Each well was then incubated with 100 micro-
liters of anti-rPFP antibody at room temperature for 4 h.
This adsorption procedure was repeated twice, and the
absorbed antibody was used for immunostaining controls.
Calculation ofPFPpositive cells
The numbers of PFP + cells infiltrated to cancer stromas
were counted in three areas of 250 x 2501i under high power
magnification with an objective micrometer. The data were
analysed for statistical significance with the non-parametric
Welch test, and the results were considered significant if the
P value was less than 0.05.
Results
PFP + cells in PBL
Specific PFP immunostaining was observed in the cytoplasm
of lymphocytes (Figure 1). PFP was detected in large lym-
phocytes and accounted for about 10% of PBL. Preimmune
rat serum or preabsorbed antibody used as a control did not
yield specific staining. These control tests were repeated on
the cytocentrifuged specimens of PBL with the same results.
Double staining showed that 18% of CD16 + cells and 9%
of CD8 + cells but none of the CD4 + cells produced PFP
(Figure 2).
PFP + cells in cancer stroma
Frozen sections of 28 colorectal cancers were evaluated for
PFP specific immunostaining. Figure 3 shows the results
obtained. PFP immunoreactivity was observed in the lym-
phocytes infiltrating to the tumour stroma, especially in the
Figure 1 PFP expression in PBL. Human PBL were stained with
anti-PFP Ab. PFP immunoreactivity is observed in the cytoplasm
of human PBL. x 800.
Figure 2 Phenotypes of PFP + cells in PBL. Human PBL were
doubly stained with anti-PFP Ab (brown reactive products) and
anti-CD8 Ab, a, anti-CD16 Ab, b, and anti-CD4 Ab, c, (blue
reactive products). x 1000.
vicinity of tumour infiltration, but only a little in the normal
epithelia. Preimmune rat serum used as a control did not
yield specific staining. These control tests were repeated on
sections of TIL with the same results.
The mean numbers of PFP + cells which were counted in
three fields on each specimen were indicated with a dot in
Figure 4. The number of PFP + cells in Dukes A was
19.0 ± 7.1 (mean ± s.d.), in Dukes B 8.9 ± 4.5 (mean ± s.d.),
and in Dukes C 3.2 ± 2.1 (mean ± s.d.). The number of
PFP + cells in Dukes A was significantly higher than in
Dukes B (P <0.01), and that in Dukes B significantly higher
than in Dukes C (P <0.01). Furthermore, the number in
Dukes A was significantly much higher than in Dukes C
(P <0.001). The populations of PFP + cells were determined
with double staining. A part of the CD16 + cells and CD8 +
cells was doubly stained by anti PFP antibody but CD4 +
cells were not doubly stained in TIL (Figure 5). PFP + cells
in CD8 + and CD16 + cells were counted. The ratios of
PFP + cells in CD8 + cells and in CD16 + cells were highest
in Dukes A, while the number of PFP + cells decreased
according to the progression of tumours. In all stages, the
ratio of PFP + cells in CD8 + cells was higher than that in
CD16 + cells (Figure 6).
Discussion
Northern blot analysis has confirmed that PFP is expressed
by human CTL and NK cells in vitro (Shinkai et al., 1988a;
Lichtenheld et al., 1988), but the expression of this protein in
vivo has not yet been shown.
Figure 3 PFP expression in TIL. Frozen sections of human
colorectal cancers were stained with anti-PFP Ab. PFP
immunoreactivity is observed in the lymphocytes infiltrated to
human colorectal cancer. x 200.PFP EXPRESSION IN TIL 241
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Figure 4 Number of PFP + cells in Dukes staging. Symbols and
vertical bars represent the mean + s.d., and a dot indicates the
frequency of PFP + cells in each specimen. Significance of
difference; *P<0.01, **P<0.001.
Figure 5 Phenotypes of PFP + cells in TIL. Frozen sections of
human colorectal cancers were doubly stained with anti-PFP Ab
(brown reactive products) and anti-CD8 Ab a, anti-CD16 Ab, b,
and anti-CD4 Ab, c, (blue reactive products). x 1000.
In this study, we first investigated PFP + cells and their
phenotypes in circulating PBL by double staining, using both
a rat anti-PFP monoclonal antibody which cross-reacts to
human PFP (Nakata et al., 1990) and antibodies against
surface markers of lymphocytes. The results demonstrated
that PFP was not expressed by all the CD8 + and CD16 +
cells, but only part of them contained PFP. In the absence of
infectious diseases, we assume that PFP is produced in a
minority of CD8 + or CD16 + cells in PBL, but that the
number of PFP + cells may rapidly increase in response to
the invasion of foreign microorganisms such as viruses. In
fact, it has been reported in animals that the number of
PFP + cells increases in response to acute viral infection
(Young et al., 1989; Young et al., 1990). The defense
mechanism of PFP against tumours can be deduced from
that against virus infection because PFP has been shown to
have a cytotoxic activity against not only virus-infected cells
but also tumour cells in vitro (Zalman et al., 1986; Shinkai et
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Figure 6 Percentage of PFP + cells in CD8 + cells and CD16 +
cells in Dukes staging.
al., 1988b). In colorectal cancer stroma, PFP + cells were
more numerous in the vicinity of tumour infiltration than in
the normal mucosa. And then the number of PFP + cells
decreased in accordance with tumour progression. PFP +
cells were not examined for cytotoxic activity against
autologous tumour cells but this finding indicates the import-
ance of PFP production for the host's immune response
against tumour invasion.
Double staining of PFP + cells showed that PFP in TIL
was mainly produced by CD8 + cells rather than CD16 +
cells, which was a different finding from that for PBL. Our
results suggest that CD8 + cells participate mainly in the
mechanism of PFP-mediated immune response to tumour cell
lysis in colorectal cancer tissues and support previous reports
that CD8 + cells play an important role in the suppression
of tumour growth (Rabinowich et al., 1987).
Many investigators have reported that the number of
CD8 + cells or CD16 + cells in TIL tends to decrease in
advanced cancer (Shinokawara et al., 1982; Ogata et al.,
1989), and several factors which show the cytotoxicity
against cancer cells have been characterised (Young & Cohn,
1987; Tschopp & Jongeneel, 1988). Our study has shown for
the first time that the ratio of PFP + cells in CD8 + cells or
CD16 + cells in TIL becomes smaller in accordance with
tumour progression. PFP may also play an important role in
the defense mechanism against tumours in cooperation with
other factors.
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